№ files_lp_3_process_9_46608
File format: docx
Character count: 46002
File size: 78 KB
Year:
2023
Region / City:
Australia
Topic:
Opioid Dependence Treatment, Pharmaceutical Benefits Scheme
Document Type:
Government Report
Organization:
Australian Government Department of Health and Aged Care
Author:
Australian Government Department of Health and Aged Care
Target Audience:
Stakeholders, policymakers, healthcare providers, public
Effective Period:
2023-07-01 and onwards
Approval Date:
2023-03-01
Modification Date:
N/A
Interim Review Outcomes Date:
2023-03-01
Note:
Contextual Description
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
XXXX
Region / city:
XXXX
Topic:
Medical Device Safety and Performance Evaluation
Document Type:
Evaluation Report
Organization / Institution:
XXXX
Author:
XXXX
Target Audience:
Regulatory Bodies, Medical Device Manufacturers
Period of Effectiveness:
XXXX
Approval Date:
XXXX
Date of Changes:
XXXX
Year:
YYYY
Region / City:
[City/Region]
Topic:
Medical Device Safety and Performance Monitoring
Document Type:
PMCF Plan
Organization:
[Manufacturer Name]
Author:
[Author Name]
Target Audience:
Regulatory Authorities, Medical Device Manufacturers
Validity Period:
YYYY/MM/DD to YYYY/MM/DD
Approval Date:
DD/MM/YYYY
Revision Date:
XXXX
Date of Changes:
YYYY/MM/DD
Year:
2015
Region / city:
International
Topic:
Medical Device Regulation
Document Type:
Official Report
Organization / Institution:
International Medical Device Regulators Forum (IMDRF)
Author:
National Competent Authority Report Working Group
Target Audience:
Medical Device Regulators, Public Health Authorities
Period of validity:
Ongoing
Approval Date:
26 March 2015
Date of amendments:
None
Year:
2016-2017
Region / city:
Australia
Topic:
Life Saving Drugs Program, Rare Diseases, Health Policy
Document type:
Government Report
Organization / institution:
Australian Government
Author:
Australian Government
Target audience:
Health policymakers, healthcare professionals, stakeholders in rare disease treatment
Period of validity:
Ongoing
Date of approval:
2014-04-09
Date of amendments:
None
Year:
2023
Region / City:
Australia
Subject:
Smoking cessation, pharmaceutical benefits
Document Type:
Report
Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Unknown
Target Audience:
Healthcare providers, policymakers
Period of Effect:
Ongoing
Approval Date:
Unknown
Date of Changes:
Unknown
Year:
2021
Region / City:
Australia
Topic:
Smoking cessation, medicines cost-effectiveness, Pharmaceutical Benefits Scheme
Document type:
Report
Organization:
Pharmaceutical Benefits Advisory Committee
Author:
Centre for Health Economics, Monash University
Target audience:
Health professionals, policy makers, Pharmaceutical Benefits Advisory Committee members
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Purpose:
Post-market review, cost-effectiveness evaluation
Clinical issue:
Smoking cessation treatment
Proposed changes to PBS restrictions:
Yes
Market size:
Pharmacological assisted quit attempts
Treatment costs and co-payments:
Yes
Market growth:
Change in quit attempts
Health outcomes:
Quit rates, relapse rates, smoking-related diseases
References:
Yes
Note:
Contextual description
Year:
2019
Region / Country:
Australia
Subject:
Pulmonary arterial hypertension medicines and subsidy policy
Document Type:
Policy review agenda item and briefing
Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Program:
Pharmaceutical Benefits Scheme (PBS)
Topic:
Post-Market Review (PMR) of PAH medicines
Medicines Mentioned:
bosentan, ambrisentan, macitentan, sildenafil, tadalafil, iloprost, riociguat, epoprostenol
Medical Classification Referenced:
WHO Functional Class II–IV pulmonary arterial hypertension
Guidelines Referenced:
2015 European Society of Cardiology / European Respiratory Society Guidelines for the diagnosis and treatment of pulmonary hypertension
Stakeholders:
PAH Reference Group, medicine sponsors including Actelion, GlaxoSmithKline, and Pfizer
Regulatory Focus:
Revision of PBS prescribing restrictions and subsidy conditions
Key Policy Changes Considered:
Extension of subsidised monotherapy to WHO Functional Class II patients, updated PAH definition, inclusion of additional WHO Group 1 PAH subtypes, removal of calcium channel blocker trial requirement, strengthened diagnostic role of right heart catheterisation
Consultation Process:
Pre-PBAC consultation with sponsors and reference group
Associated Meetings:
PBAC meetings in November 2018, March 2019, and planned July 2019 review discussion
Related Policy Activity:
Planned stakeholder meeting on PAH combination therapy scheduled for May 2019
Year:
2023
Country:
Australia
Topic:
Opioid dependence treatment
Document type:
Information overview
Program:
ODT Community Pharmacy Program
Administering body:
Pharmacy Programs Administrator
Related scheme:
Pharmaceutical Benefits Scheme
Legislative framework:
National Health (Highly specialised drugs program) Special Arrangement 2021
Target audience:
Community pharmacists and hospital pharmacists
Effective date:
1 July 2023
Funding period:
2023–24 to 2026–27
Medicines covered:
Methadone, buprenorphine, buprenorphine with naloxone
Regulatory classification:
Schedule 8 controlled drugs
Source type:
Government health program guidance
Note:
Year
Topic:
Tobacco dependence treatment
Document type:
Protocol
Organization / institution:
Local Stop Smoking Services (LSSS)
Target audience:
Healthcare professionals, practitioners in LSSS
Year:
2024
Region / city:
Australia
Theme:
Opioid dependence treatment, Pharmaceutical Benefits Scheme
Document type:
FAQ
Organization / institution:
Pharmaceutical Benefits Scheme
Author:
Pharmaceutical Benefits Scheme
Target audience:
Healthcare providers, prescribers, pharmacists
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Note:
Year
Topic:
Tobacco Dependence
Document type:
Clinical Guideline
Target audience:
All employees involved in providing care for patients who smoke
Year:
2019
Region / City:
Australia
Topic:
Opiate Dependence, Pharmaceutical Approval
Document Type:
Application for Pharmaceutical Listing
Organization / Institution:
PBAC, TGA
Author:
Indivior Pty Ltd
Target Audience:
Medical professionals, Pharmaceutical regulatory bodies
Effective Period:
From July 2019
Approval Date:
18 July 2019
Amendment Date:
17 July 2019
Year:
[insert year]
Region / City:
[insert region/city]
Topic:
Drugs of dependence, pain management, mental health treatment
Document Type:
Therapy Agreement
Organ / Institution:
[Insert practice name]
Author:
[insert author, if available]
Target Audience:
Patients receiving therapy for drugs of dependence
Period of Effectiveness:
[insert start date]
Approval Date:
[insert approval date]
Date of Revisions:
[insert revision date]
Year:
2020
Region / City:
United Kingdom
Topic:
Dependence Forming Medications
Document Type:
Prescribing Guide
Organisation:
Royal College of General Practitioners (RCGP)
Author:
Royal College of General Practitioners (RCGP)
Target Audience:
Healthcare professionals, particularly general practitioners
Period of validity:
Not specified
Approval Date:
15th October 2020
Date of Changes:
Not specified
Year:
2018
Region / city:
Greater Manchester
Theme:
Alcohol dependence treatment
Document type:
Protocol
Organization:
Greater Manchester Mental Health NHS Foundation Trust
Author:
Not specified
Target audience:
Healthcare professionals
Period of validity:
Until 22/08/2021
Approval date:
22/08/2018
Date of changes:
N/A
Year:
2023
Region / City:
London, United Kingdom
Topic:
Alcohol dependence, Alzheimer’s disease, neuroinflammation, cognitive impairment
Document type:
Research article
Organization / Institution:
Imperial College London, University of Edinburgh
Author:
Dr. Ashwin Venkataraman, Dr. Nicola Kalk, Dr. Gavin Sewell, Professor Craig W Ritchie, Professor Anne Lingford-Hughes
Target audience:
Researchers, clinicians, and academics in the field of neuroscience, psychiatry, and dementia
Period of validity:
N/A
Date of approval:
N/A
Date of changes:
N/A
Date:
April 2021
Geographic scope:
Australian Capital Territory; New South Wales; Queensland; Western Australia; South Australia; Tasmania; Northern Territory; Victoria
Country:
Australia
Subject:
Opioid dependence treatment programs
Document type:
Interjurisdictional summary report
Source of information:
Jurisdictional input responses and publicly available sources (NT)
Focus:
Funding arrangements, patient fees, prescriber requirements, pharmacy participation, correctional facility access
Medications referenced:
Long acting injectable buprenorphine (LAIB); buprenorphine; buprenorphine/naloxone; depot buprenorphine (BPN)
Related initiatives:
Opioid Treatment Program Strategic Action Plan (NSW); SafeScript implementation (VIC)
Timeframe referenced:
2020–21 (budget figures)
Year:
1989
Region / City:
Bali, Indonesia
Subject:
Plant pathology, rice tungro disease
Document Type:
Research article
Institution:
Food Crop Protection Center VII; Directorate of Crop Protection, Indonesia
Authors:
N. S. Astika, N. Suwela, G. N. Aryawan, Y. Suzuki
Target Audience:
Plant pathologists, agronomists, crop protection specialists
Research Period:
Late 1989, dry season
Variety Studied:
Krueng Aceh, IR36, IR64
Observation Duration:
5 weeks
Publication:
International Rice Research Newsletter, 1992
Volume / Issue:
17 (3)
Pages:
19-20
Year:
2020
Region / City:
Kolkata, West Bengal
Subject:
Alcohol dependence, de-addiction, psychiatric study
Document Type:
Research Study
Institution:
Institute of Psychiatry - COE, Kolkata
Authors:
Atasi Rani Mandal, Gita Purkait, Chandrima Maity
Target Audience:
Medical and psychiatric professionals, researchers in alcohol dependence
Duration of Study:
December 2019 to February 2020
Date of Approval:
Not specified
Date of Modifications:
Not specified
Keywords:
Alcohol, Dependency Level, Influencing Factors, Alcoholic Person, De-addiction, Alcoholism
Methodology:
Descriptive Survey, Convenience Sampling, Standardized Tools
Sample Size:
100
Sampling Method:
Non-probability Convenience Sampling
Tool Used:
AUDIT, SOCRATES Rating Scale, Structured Checklists
Content Validity:
95-100% Agreement from Experts
Context:
This research identifies the level of alcohol dependency, influencing factors, challenges faced by individuals with alcohol dependence, and their attitudes towards de-addiction through a study conducted in a psychiatric hospital in Kolkata.
Year:
1989
Jurisdiction:
Australian Capital Territory
Subject:
Controlled substances and drug offences
Document type:
Legislation
Authority:
Australian Capital Territory Legislative Assembly
Author:
Parliamentary Counsel’s Office
Effective period:
14 May 2020 – 19 February 2021
Amendments:
Amendments under Legislation Act 2001, part 11.3 (Editorial changes)
Penalty units:
$160 for individuals, $810 for corporations
Commencement:
As specified in the Act and subsequent amendments
Modifications:
Current modifications indicated with symbol M in text
Uncommenced provisions:
Indicated with symbol U in text
Structure:
Includes Preliminary, Interpretation, Offences, Enforcement, Miscellaneous, Dictionary, Endnotes